180 reports of this reaction
3.5% of all ETOMIDATE reports
#4 most reported adverse reaction
ANXIETY is the #4 most commonly reported adverse reaction for ETOMIDATE, manufactured by Hospira, Inc.. There are 180 FDA adverse event reports linking ETOMIDATE to ANXIETY. This represents approximately 3.5% of all 5,192 adverse event reports for this drug.
Patients taking ETOMIDATE who experience anxiety should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANXIETY is moderately reported among ETOMIDATE users, representing a notable but not dominant share of adverse events.
In addition to anxiety, the following adverse reactions have been reported for ETOMIDATE:
The following drugs have also been linked to anxiety in FDA adverse event reports:
ANXIETY has been reported as an adverse event in 180 FDA reports for ETOMIDATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANXIETY accounts for approximately 3.5% of all adverse event reports for ETOMIDATE, making it a notable side effect.
If you experience anxiety while taking ETOMIDATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.